Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

MK-6482-013 : Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Kidney<br/>CancersCancer LocationKidney
Cancers

Systemic therapy | Urinary systemKidney,Renal cell carcinoma

Trial Overview Read MoreRead more

This phase II trial is trying to understand the safety and effectiveness of using chemotherapy (belzutifan) in patients with advanced renal cell carcinoma.
 

This trial is treating patients with advanced renal cell carcinoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma

Commercial Sponsor

Merck

Summary

Participants will either receive Dose A (standard dose) or Dose B (higher dose) of belzutifan by oral administration, once a day (QD), until disease progression or discontinuation.

Recruiting Hospitals Read MoreRead more

Box Hill Hospital Medical Oncology
Box Hill
Lauren Mitchell
lauren.mitchell@monash.edu
03 9094 9544

Peninsula Health
Frankston
Ms Diane Canning
dcanning@phcn.vic.gov.au
03 9784 8224

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next